Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11564487 | 0.92 | MAPT (0.51) | GSK3BHTTMAPTKDM4EKMT2A | |
| SCHEMBL9259272 | 0.83 | GSK3B (0.45) | GSK3BHTTADRB2ADRB1ADRB3 | |
| SCHEMBL7116483 | 0.81 | GSK3B (0.49) | GSK3BMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL1565767 | 0.81 | HTT (0.48) | GSK3BHTTADRB2ADRB1ADRB3 | |
| SCHEMBL1565766 | 0.81 | HTT (0.48) | GSK3BHTTADRB2ADRB1ADRB3 | |
| SCHEMBL8224397 | 0.81 | HTT (0.48) | GSK3BHTTADRB2ADRB1ADRB3 | |
| SCHEMBL9727087 | 0.80 | GSK3B (0.52) | GSK3BHTTMAPTKDM4EGAA | |
| SCHEMBL20943229 | 0.79 | HTT (0.47) | GSK3BHTTADRB2ADRB1ADRB3 | |
| SCHEMBL14448526 | 0.79 | HTT (0.47) | GSK3BHTTADRB2ADRB1ADRB3 | |
| SCHEMBL8881032 | 0.78 | ESR1 (0.54) | MAPTKMT2ALMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223307-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4582420-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| CN-118063438-A | MDM2/MDMX double-target inhibitor compound, prodrug, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2024-05-24 | — | — | CN | disclosed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| EP-1948629-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | GSK3B 3470/4885HTT 2233/4885ADRB2 322/4885 |
| US-20250223307-A1 | MDM2/MDMX DOUBLE-TARGET INHIBITOR COMPOUND, PRODRUG, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | MDM2, TP53, TP53BP1 | GSK3B 73/4885HTT 3514/4885ADRB2 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.